Clinical Investigation to Assess a New Artificial Urinary Sphincter to Treat Urinary Incontinence in Men

NCT ID: NCT05547672

Last Updated: 2024-05-16

Basic Information

• Recruitment Status: ACTIVE_NOT_RECRUITING
• Clinical Phase: NA
• Total Enrollment: 6 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2022-08-31
• Study Completion Date: 2025-06-30

Brief Summary

Prospective multicenter study designed to test the feasibility of the UroMems Artificial Urinary Sphincter.

Detailed Description

This study is a prospective, open-label, non-randomized, multi-center, single-arm, study with subjects acting as their own control designed to test the feasibility of a new artificial urinary sphincter the UroMems eAUS (investigational name of device called UroActive).

Conditions

Urinary Incontinence,Stress

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

UroMems artificial urinary sphincter

Male adults (18+) with urinary incontinence with reduced outlet resistance due to intrinsic sphincter deficiency.

Intervention: device (UroMems artificial urinary sphincter)

Group Type: EXPERIMENTAL

UroMems artificial urinary sphincter

Intervention Type: DEVICE

Implantation of the device

Interventions

UroMems artificial urinary sphincter

Implantation of the device

Intervention Type: DEVICE

Eligibility Criteria

Inclusion Criteria

• Aged >18 years old
• Male patient
• Cognitively able and willing to sign an informed consent
• Stable medication regimen (including prescription, over the counter, and supplements) for the past 3 months
• Able and willing to comply with follow-up investigations, including maintaining consistent medication use and fluid intake through the primary endpoints
• Has adequate cognitive and manual capabilities to operate the UroMems eAUS System as assessed by the investigator
• Is an appropriate surgical candidate and has no medical or mental condition that would interfere with study procedures or confound study outcomes as assessed by the investigator
• Life expectancy ≥ 5 years as assessed by the investigator
• Affiliated with an appropriate social security system
• Has failed or is not a candidate for other treatments for urinary incontinence, either surgical or conservative, including slings, Pro-ACT, etc. (excluding other AUS devices)
• Negative urine culture prior to the procedure
• Urinary incontinence assessed by investigator with at least ≥ 50 g in 24-hour pad-weight tests
• Clinically insignificant post-void residual (PVR) urine defined as < 50 ml and/or no greater than 10% of the voided volume
• Complains of urine leakage on coughing, laughing, and/or moving and/or presence of orthostatic urine leakage by self-report as recorded in baseline bladder diary

Exclusion Criteria

• Currently enrolled or plans to enroll in another investigational device or clinical drug trial or has completed an investigational study within 3 months
• Vulnerable patient (patient deprived of their liberty due to a judicial or administrative decision, patient suffering from psychiatry troubles preventing him from giving his consent, patients hospitalized for reason other than the current clinical investigation, patient under 18 years of age, patient under tutelage, patient having withdrawn his consent)
• Patients whom the investigator determines to be poor candidate for surgical procedures and/or anesthesia due to physical or mental conditions
• Patient presenting one or several contraindications of the device
• Any planned procedure requiring urethral catheterization 12 months after implant procedure (include intermittent catheterization) except for diagnostic purposes
• Known allergy to UroMems eAUS implantable components
• Known allergy to intravenous iodine
• Abnormal Prostate Screening Antigen (PSA), according to site's laboratory standards, unless further investigation confirms the absence of primary prostate cancer or local recurrence assessed by investigator.
• Uncontrolled diabetes mellitus defined as persistent blood sugar level recordings of >12 mmol/l (216 mg/dl) and a glycosylated hemoglobin (HbA1C) of >9% (75 mmol/mol) over the preceding 3 months
• History of bleeding diathesis or cannot stop usage of an anti-coagulant until the International Normalized Ratio (INR) is below 1.5 or quick value >70
• Any genito-urinary malignancies which are not in remission for at least 2 years or considered cured, except prostate cancer
• Previous AUS implant
• Currently has another Active Implantable Medical Device (AIMD) implanted
• Urge incontinence, mixed incontinence (MI) with a predominant urgency component
• Overflow urinary incontinence
• Neurogenic bladder dysfunction that is not treatable or controllable by pharmacological or any alternative methods
• Abnormal or poor bladder compliance defined as being <30 ml/ cm H2O
• Bladder neck or urethral stricture that may require any long-term instrumental treatment

• Minimum Eligible Age: 18 Years
• Eligible Sex: MALE
• Accepts Healthy Volunteers: No

Sponsors

UroMems SAS

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Emmanuel Chartier-Kastler

Role: PRINCIPAL_INVESTIGATOR

Groupe Hospitalier Pitié-Salpêtrière

Locations

CHU Nantes

Nantes, , France

Groupe Hospitalier Pitié-Salpêtrière

Paris, , France

Countries

France

Other Identifiers

CIP CSO2012031234

Identifier Type: -

Identifier Source: org_study_id